RMMS Defeats Motion for Preliminary Injunction Involving Generic Ibandronate Products

March 14, 2012 | Small Molecules

03/14/2012 On March 14, 2012, RMMS successfully defeated Plaintiffs Hoffman-La Roche and Genentech Inc.’s motion for preliminary injunction against the firm’s clients, Watson Pharmaceuticals, Inc. Watson Laboratories, Inc., Watson Pharma, Inc., Cobalt Pharmaceuticals, Inc. and Cobalt Laboratories, Inc. (‘Watson’). After briefing and hearing argument and witness testimony on Plaintiffs’ motion to enjoin Watson from launching its generic version of Boniva®, the U.S. District Court for the District of New Jersey denied Plaintiffs’ motion, holding that Plaintiffs had failed to show that they were likely to succeed on the merits of their patent infringement claims at trial. Deanne Mazzochi, William Rakoczy, Paul Molino, Tara Raghavan, and Eric Hunt are counsel for Watson. This victory continues to place RMMS at the forefront of generic challenges to brand pharmaceutical patents.